View Older Stories View More Recent Stories

Feb 15, 2022 07:30AM Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2022
Feb 7, 2022 07:30AM Zai Lab Announces Upcoming Presentation at February Investor Conference
Jan 12, 2022 07:30AM Zai Lab Announces First Patient Treated in Greater China in PANOVA-3 Phase 3 Pivotal Trial of Tumor Treating Fields in Pancreatic Cancer
Jan 6, 2022 07:36AM Zai Lab Limited (ZLAB) Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
Jan 6, 2022 07:30AM Zai Lab Announces NDA Acceptance of Margetuximab for Patients with Pretreated Metastatic HER2-Positive Breast Cancer in China by the NMPA
Dec 29, 2021 07:30AM Zai Lab Announces Upcoming Presentations at January Investor Conferences
Dec 22, 2021 07:30AM Zai Lab Announces Promotion of Harald Reinhart, M.D. to President and Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases
Dec 20, 2021 06:30AM Zai Lab (ZLAB) Partner argenx Announces FDA Approval of VYVGART in Generalized Myasthenia Gravis
Dec 17, 2021 06:09PM Zai Lab Partner argenx Announces U.S. Food and Drug Administration (FDA) Approval of VYVGART™ (efgartigimod alfa-fcab) in Generalized Myasthenia Gravis
Dec 16, 2021 11:57AM Paratek Pharmaceuticals (PRTK) Partner Zai Lab (ZLAB) Gains China Approval for NUZYRA
Dec 16, 2021 11:36AM China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment of Bacterial Pneumonia and Skin Infections 
Dec 16, 2021 04:43AM China NMPA Approves NUZYRA® as a Category 1 Innovative Drug for the Treatment of Patients with Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (AB
Dec 3, 2021 07:30AM Zai Lab Limited (ZLAB) Announces Inclusion of ZEJULA in China’s National Reimbursement Drug List
Dec 3, 2021 07:30AM Zai Lab Announces Inclusion of ZEJULA® (Niraparib) in China’s National Reimbursement Drug List for First-Line Ovarian Cancer
Nov 30, 2021 07:32AM Zai Lab Limited (ZLAB) Reports Positive Topline Results from Phase 3 PRIME Study of ZEJULA
Nov 30, 2021 07:30AM Zai Lab Announces Positive Topline Results from Phase 3 PRIME Study of ZEJULA® (Niraparib) as First-Line Monotherapy Maintenance Treatment in Chinese Women with Platinum-Responsive Advanced Ovarian C
Nov 23, 2021 07:30AM Zai Lab Announces Upcoming Presentations at December Investor Conferences
Nov 22, 2021 07:32AM Zai Lab Limited (ZLAB) Appoints Richard Gaynor to its Board
Nov 22, 2021 07:30AM Zai Lab Appoints Richard Gaynor, MD, to its Board of Directors
Nov 16, 2021 07:30AM Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in CIDP
Nov 15, 2021 07:30AM Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Pemphigus
Nov 11, 2021 07:30AM Zai Lab Announces First Patient Dosed in Greater China in Global Registrational Clinical Trial of Efgartigimod in Primary Immune Thrombocytopenia
Nov 9, 2021 04:10PM Zai Lab Announces Third Quarter 2021 Financial Results and Corporate Updates
Nov 9, 2021 08:00AM Zai Lab and Blueprint Medicines Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 9, 2021 08:00AM Blueprint Medicines and Zai Lab Announce Strategic Collaboration and License Agreement for BLU-945 and BLU-701 in Greater China
Nov 9, 2021 07:37AM PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 9, 2021 07:04AM Karuna Therapeutics Inc. (KRTX) and Zai Lab (ZLAB) Announces Collaboration for Development, Manufacturing, and Commercialization of KarXT in China
Nov 9, 2021 07:00AM Zai Lab and Karuna Therapeutics Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 9, 2021 07:00AM Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
Nov 4, 2021 07:30AM Zai Lab Announces Upcoming Presentations in November Investor Conferences
Oct 26, 2021 07:30AM Zai Lab to Announce Third Quarter 2021 Financial Results
Oct 25, 2021 07:30AM Zai Lab Announces First Patient Treated in Greater China Portion of Potentially Registrational, Global Phase 2 Study of Odronextamab
Oct 20, 2021 04:06PM Zai Lab Limited's (ZLAB) ZL-1102 Achieves Proof of Concept in Phase 1b Psoriasis Study
Oct 20, 2021 04:05PM ZL-1102, Zai Lab’s Internally Developed Novel Human VH Antibody Fragment, Achieved Proof of Concept in Phase 1b Psoriasis Study
Oct 13, 2021 10:01AM Geneseeq and Zai Lab (ZLAB) Announce Strategic Collaboration to Advance Cancer Drug R&D
Oct 13, 2021 10:00AM Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D
Oct 11, 2021 07:30AM Zai Lab Announces Upcoming Presentations in October Investor Conferences
Oct 5, 2021 07:32AM Zai Lab Limited (ZLAB) Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China
Oct 5, 2021 07:30AM Zai Lab Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced HER2+ Breast Cancer in Greater China
Oct 4, 2021 09:10AM Zai Lab Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for Repotrectinib Treatment in Patients With NTRK-Positive, TKI-Pretreated Advanced Solid Tumors
Oct 4, 2021 07:30AM Novocure and Zai Lab Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Oct 4, 2021 07:30AM Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of Tumor Treating Fields Plus Chemotherapy as First-Line Treatment in Gastric Cancer in China
Sep 22, 2021 12:22PM Zai Lab Holds Virtual Research and Development Day
Sep 16, 2021 07:30AM Zai Lab Expands U.S. Operations to Join the Cambridge Biotechnology Community
Sep 14, 2021 07:31AM Zai Lab Limited's (ZLAB) Bemarituzumab (FPA144) Granted Breakthrough Therapy Designation in China
Sep 14, 2021 07:30AM Zai Lab Announces Breakthrough Therapy Designation Granted for Bemarituzumab (FPA144) in China
Sep 9, 2021 07:30AM Zai Lab to Host Virtual Research and Development Day on September 22, 2021
Aug 24, 2021 07:30AM Zai Lab Announces Upcoming Presentations in September Investor Conferences
Aug 9, 2021 04:30PM Zai Lab Announces Second Quarter 2021 Financial Results and Corporate Updates
Aug 4, 2021 07:30AM Schrödinger and Zai Lab Announce a Global R&D Collaboration in Oncology
View More Recent Stories View Older Stories